Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Novavax, Inc’s stock clocked out at $6.70, up 0.52% from its previous closing price of $6.67. In other words, the price has increased by $0.52 from its previous closing price. On the day, 5.68 million shares were traded. NVAX stock price reached its highest trading level at $7.35 during the session, while it also had its lowest trading level at $6.655.
Ratios:
To gain a deeper understanding of NVAX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.97 and its Current Ratio is at 0.98.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on February 28, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On July 30, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral but kept the price unchanged to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 14 ’25 when YOUNG JAMES F bought 4,000 shares for $6.10 per share.
King Rachel K. sold 4,150 shares of NVAX for $37,435 on Dec 13 ’24. The Director now owns 14,770 shares after completing the transaction at $9.02 per share. On Dec 31 ’24, another insider, YOUNG JAMES F, who serves as the Director of the company, sold 5,400 shares for $8.00 each. As a result, the insider received 43,200 and left with 51,760 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1143135488 and an Enterprise Value of 418813344. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.58. Its current Enterprise Value per Revenue stands at 0.614 whereas that against EBITDA is -2.283.
Stock Price History:
The Beta on a monthly basis for NVAX is 3.20, which has changed by 0.54965353 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $23.86, while it has fallen to a 52-week low of $3.92. The 50-Day Moving Average of the stock is -6.98%, while the 200-Day Moving Average is calculated to be -32.04%.
Shares Statistics:
It appears that NVAX traded 5.10M shares on average per day over the past three months and 6723370 shares per day over the past ten days. A total of 160.42M shares are outstanding, with a floating share count of 146.57M. Insiders hold about 8.87% of the company’s shares, while institutions hold 59.67% stake in the company. Shares short for NVAX as of 1744675200 were 41028051 with a Short Ratio of 8.05, compared to 1741910400 on 37551429. Therefore, it implies a Short% of Shares Outstanding of 41028051 and a Short% of Float of 31.780002000000003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Novavax, Inc (NVAX) is a result of the insights provided by 5.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.2, with high estimates of $0.64 and low estimates of $-0.36.
Analysts are recommending an EPS of between $2.69 and $-1.3 for the fiscal current year, implying an average EPS of $0.49. EPS for the following year is $0.33, with 6.0 analysts recommending between $2.25 and $-1.15.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $204.07M. It ranges from a high estimate of $601M to a low estimate of $31.9M. As of the current estimate, Novavax, Inc’s year-ago sales were $93.86MFor the next quarter, 4 analysts are estimating revenue of $155.18M. There is a high estimate of $200M for the next quarter, whereas the lowest estimate is $77M.
A total of 7 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.1B, while the lowest revenue estimate was $325M, resulting in an average revenue estimate of $572.55M. In the same quarter a year ago, actual revenue was $682.16MBased on 6 analysts’ estimates, the company’s revenue will be $520.64M in the next fiscal year. The high estimate is $888.6M and the low estimate is $320.58M.
